BiotechTube

Nirsevimab + Placebo

Phase 3Active
0 views this week 0 watching⚡ Active
Interest: 44/100
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Lower Respiratory Tract Infection

Conditions

Lower Respiratory Tract Infection

Trial Timeline

Nov 24, 2021 → Nov 24, 2025

NCT ID
NCT05110261

About Nirsevimab + Placebo

Nirsevimab + Placebo is a phase 3 stage product being developed by AstraZeneca for Lower Respiratory Tract Infection. The current trial status is active. This product is registered under clinical trial identifier NCT05110261. Target conditions include Lower Respiratory Tract Infection.

What happened to similar drugs?

5 of 13 similar drugs in Lower Respiratory Tract Infection were approved

Approved (5) Terminated (1) Active (7)
✅Tamsulosin + SolifenacinAstellas PharmaApproved
✅Tamsulosin + SolifenacinAstellas PharmaApproved
✅Tamsulosin OCASAstellas PharmaApproved
✅GabapentinPfizerApproved
✅CiprofloxacinIterum TherapeuticsApproved
🔄tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/6 mg) + tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/9 mg)Astellas PharmaPhase 3
🔄DuloxetineShionogiPhase 3

Hype Score Breakdown

Clinical
17
Activity
12
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05110261Phase 3Active

Competing Products

20 competing products in Lower Respiratory Tract Infection

See all competitors
ProductCompanyStageHype Score
JSP191Jasper TherapeuticsPhase 1
11
solifenacin succinate + tamsulosin hydrochloride + Placebo to solifenacin + Placebo to tamsulosinAstellas PharmaPhase 2
35
SolifenacinAstellas PharmaPre-clinical
26
Tamsulosin + SolifenacinAstellas PharmaApproved
43
Vesitirim™ (Solifenacin)Astellas PharmaPre-clinical
26
Mirabegron + PlaceboAstellas PharmaPhase 2
35
tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/6 mg) + tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/9 mg)Astellas PharmaPhase 3
40
tamsulosin hydrochloride + solifenacin succinate + PlaceboAstellas PharmaPhase 2
35
Tamsulosin + SolifenacinAstellas PharmaApproved
43
Tamsulosin OCASAstellas PharmaApproved
43
DuloxetineShionogiPhase 3
40
Duloxetine + PlaceboShionogiPhase 3
40
AZD1656AstraZenecaPhase 1
29
RSVpreF + PlaceboPfizerPhase 3
44
GabapentinPfizerApproved
43
Erythropoiesis-stimulating agents (ESAs) + Luspatercept + Lenalidomide + Hypomethylating agents (HMAs) + Reb blood cell transfusionBristol Myers SquibbPre-clinical
30
ALX-0171 1.5 mg/kgSanofiPhase 2
27
ALX-0171 3.0 mg/kg + ALX-0171 6.0 mg/kg + ALX-0171 9.0 mg/kgSanofiPhase 2
35
ALX-0171 Dose 1 + ALX-0171 Dose 2 + PlaceboSanofiPhase 2
27
Placebo + Hydrocodone bitartrateUCBPhase 3
40